Meropenem-Vaborbactam
Sponsors
Rempex Pharmaceuticals Inc., Melinta Therapeutics, Inc., Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.), Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC), National University of Singapore
Conditions
Acute PyelonephritisAcute Pyelonephritis (AP)Bloodstream InfectionCRE ColonizationCarbapenem Resistant Bacterial InfectionCarbapenem-resistant EnterobacteralesComplicated Urinary Tract InfectionComplicated Urinary Tract Infection (cUTI)
Phase 1
Phase 2
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
Active, not recruitingNCT06672978
Start: 2025-06-03End: 2027-07-01Target: 66Updated: 2026-09-10
A Multi-Center, Open-Label, Single-Arm, Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vabomere (meropenem-vaborbactam) in the Treatment of Children with Complicated Urinary Tract Infection, Including Acute Pyelonephritis
RecruitingCTIS2024-516360-29-00
Start: 2025-04-25Target: 36Updated: 2025-07-28
Phase 3
Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP
CompletedNCT02166476
Start: 2014-11-20End: 2016-04-28Updated: 2018-06-11
A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
WithdrawnNCT03006679
Start: 2018-08-31End: 2020-12-31Updated: 2019-01-11
Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver Transplantation
Not yet recruitingNCT07759453
Start: 2026-10-01End: 2029-09-30Target: 168Updated: 2026-08-12